Tuesday 13 October 2026
Export CAPR’s income statement to Excel — free account
Capricor Therapeutics, Inc.
CAPR Healthcare Biotechnology
Capricor Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22.3 million, down 11.5% from fiscal 2023. In the quarter to June 2026, revenue fell 7.92%, EPS fell 22.8% and free cash flow fell 72.9%, each against the same quarter a year earlier.
6.88
0.59
−7.90%
Follow CAPR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(107.79%) | (46.56%) | (56.40%) | (73.70%) | |
| (74.74%) | (39.91%) | (47.74%) | (51.53%) | ||
ROIC |
0.00% | 0.00% | (80,860.30%) | (1,019.73%) | |
Return on Tangible Assets |
(97.76%) | (34.39%) | (41.23%) | (52.71%) | |
Average Days of Receivables |
0.00 | 0.00 | — | — | |
Free Cash Flow per Share |
0.56 | 3.85 | 2.55 | 2.26 | |
Free Cash Flow |
25.42 | 179.06 | 146.63 | 130.91 | |
Capital Expenditures |
86.46 | 248.87 | 239.27 | 234.91 | |
| Other line items | |||||
Cash ROIC |
13.93% | 28.70% | 26.31% | 27.04% | |
Accounts Receivable Turnover |
0.00 | 0.00 | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.74 | 0.66 | 0.81 | 0.80 | |
Depreciation/Fixed assets |
0.16 | 0.10 | 0.06 | 0.02 | |
Capex/Depreciation |
49.06 | 131.75 | 144.18 | 278.95 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.34) | (1.50) | (1.61) | (1.80) | |
Capex per Share |
1.89 | 5.35 | 4.17 | 4.06 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates